Quick Answer
Bioventus Inc. reported Research And Development Expense of $12.11 million for the year ending 2025.
- Bioventus Inc. showed a decrease of -13.2% in Research And Development Expense from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.15 million | Q2 2020: $2.60 million | Q3 2020: $3.57 million | Q1 2021: $947.0 thousand | Q2 2021: $4.84 million | Q3 2021: $6.15 million | Q1 2022: $6.93 million | Q2 2022: $6.37 million | Q3 2022: $4.61 million | Q1 2023: $3.77 million | Q2 2023: $3.40 million | Q3 2023: $3.02 million | Q1 2024: $2.63 million | Q2 2024: $4.21 million | Q3 2024: $3.84 million | Q1 2025: $3.01 million | Q2 2025: $3.17 million | Q3 2025: $2.92 million.
- Over the full 7 years of available data (2019 to 2025), Bioventus Inc.'s Research And Development Expense has grown by 9.6%.
- Historical annual values: Fiscal year 2025: $12.11 million | Fiscal year 2024: $13.95 million | Fiscal year 2023: $13.45 million | Fiscal year 2022: $23.85 million | Fiscal year 2021: $19.04 million | Fiscal year 2020: $11.20 million | Fiscal year 2019: $11.06 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: